Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Director/PDMR Shareholding

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091002:RnsB1098A
                                                                                                                       .
RNS Number : 1098A  
  
ABCAM Plc  
  
02 October 2009  
  
 
  For immediate release   2 October 2009  
  
  
 ("Abcam" or "the Company")  
  
Director's Dealings   
  
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that 
markets antibodies via its own online catalogue, announces the following 
transactions undertaken by Directors of the Company:  
  
On 30 September 2009, Jonathan Milner, an Executive Director of the Company, 
exercised share options over 53,571 ordinary shares of 1 pence each in the 
Company at an exercise price of 280p per share. Following this transaction, Dr 
Milner's total beneficial interest in the Company is 6,138,851 ordinary shares 
representing approximately 17.2 per cent. of the current issued share capital of 
the Company.   
  
Also on 30 September 2009, Jim Warwick, an Executive Director of the Company, 
exercised share options over 20,000 ordinary shares of 1 pence each in the 
Company at an exercise price of 280p per share. Following this transaction, Mr 
Warwick's total beneficial interest in the Company is 853,520 ordinary shares 
representing approximately 2.4 per cent. of the current issued share capital of 
the Company.   
  
For further information please contact:  
  
 
  Abcam                                               + 44 (0) 1223 696000   
  Jonathan Milner, Chief Executive Officer                                   
  Jeffrey Iliffe, Chief Financial Officer                                    
                                                                             
  Numis Securities                                    + 44 (0) 20 7260 1000  
  Michael Meade / Nick Westlake - Nominated Adviser                          
  James Black - Corporate Broking                                            
                                                                             
  Buchanan Communications                             + 44 (0) 20 7466 5000  
  Mark Court / Mary-Jane Johnson / Stasa Filiplic                            
  
  
Notes for editors:  
  
About Abcam plc  
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA and 
Tokyo, Japan. Abcam was admitted to AIM in November 2005 and trades under the 
ticker symbol ABC. The Company produces and distributes its own and third-party 
produced antibodies to academic and commercial users throughout the world. 
Product ordering is available through the Company's website www.abcam.com, where 
customers are also able to access up-to-date and detailed technical product data 
sheets. All the antibodies are sold under the Abcam brand name and the Company's 
vision is to build the world's largest online resource of high-quality and 
commercially viable antibodies. Abcam now has an online catalogue of over 52,000 
products, most of which are antibodies, from over 250 suppliers and employs 237 
staff in its three operating companies.  
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
RDSVFLFBKBBBFBK  
  

---

back to RNS news